Olympus (7733) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 FY2026 declined 12% year-over-year to JPY 206.5 billion, with major markets except APAC underperforming due to tough comps, delayed purchases, and external headwinds.

• Adjusted operating profit dropped 65% year-over-year to JPY 13.2 billion, with margin falling to 6.4% due to lower revenue and higher SG&A, including R&D.

• U.S. performance was impacted by prior year strength, delayed orders ahead of new launches, and FDA import alerts; China faced ongoing Buy China policy pressures and competitive headwinds.

• Management is focused on cost control, innovation, and execution, with Project Elevate nearing completion and new product launches expected to drive recovery.

• A joint venture was established with Revival Healthcare Capital to accelerate endoluminal robotics innovation.

Financial highlights

• Consolidated revenue: JPY 206.5 billion, down 12% year-over-year; gross margin: 65.4%.

• Adjusted operating profit: JPY 13.2 billion, down 65% year-over-year; margin at 6.4%.

• Operating profit: JPY 16.6 billion, significantly down year-over-year; net profit: JPY 9.0 billion, down 38%.

• Free cash flow: negative JPY 32.7 billion; adjusted free cash flow: negative JPY 17.5 billion.

• Equity ratio at quarter-end: 50.8%, down 1.7 points from prior year-end.

Outlook and guidance

• Full-year revenue forecast revised to JPY 998 billion, flat year-over-year but up over 3% after FX adjustment.

• Adjusted operating profit forecast: JPY 157 billion, margin 15.7%; operating profit guidance lowered to JPY 136 billion.

• Profit attributable to owners expected at JPY 94 billion, EPS JPY 85.

• Year-end dividend planned at JPY 30 per share, up JPY 10; share buyback of JPY 50 billion ongoing.

• Guidance revision reflects impacts from U.S. tariffs and FDA import alerts; management confident in recovery from Q2 onwards.